Explore UCD

UCD Home >

What we do

On this page

infographic highlighting successes in 2023, including over 500 patients enrolled onto studies, over 50 publications, 9 new team members, and 17 new studies

About our Cluster

The UCD Cancer Trials Cluster is a collaborative initiative between UCD, Ireland’s largest university, and its clinical partners, St Vincent’s University Hospital, the Mater Misericordiae University Hospital, and the Cancer Clinical Research Trust. Formed in 2022, our vision is:

to be an internationally distinguished Cancer Trials Cluster that measurably enhances the health of cancer patients through high quality innovative clinical trial research.

The UCD Cancer Trials Cluster contributes significantly to the (opens in a new window)St Vincent's UCD Cancer Centre and the OECI (Organisation of European Cancer Institutes) affiliations of both St Vincent's and the Mater Misericordiae University Hospitals. 

What sets us apart? We're building upon the remarkable accomplishments of our clinical trial units and UCD's Clinical Research Centre. Together, we're embarking on an ambitious journey to boost clinical research and enhance patient outcomes in the fields of oncology and haematology.

So, what's our plan? Let's take a closer look at our strategic objectives:

  1. Increasing Patient Participation: We aim to provide more patients with access to cancer clinical trials, increasing the number by 10% before 2026. 
  2. Expanded Access:  We're dedicated to providing patients with wider access to a range of cancer trials, including early and advanced stages of common cancer types. We're also committed to exploring rarer cancer types that align with the expertise of our investigators.
  3. Fostering Collaboration: Collaboration is key to our success and together, we can achieve change. We're focused on creating a supportive research environment, not only within our cluster but also by deepening our collaborations on a national and international scale. 
  4. Training the Future: We're passionate about nurturing the next generation of clinical trialists in the field of cancer. Our cluster is dedicated to developing exceptional clinical research programs that serve as training grounds for these future experts.
  5. Engaging Patients and the Public: We believe in going beyond mere participation. We want to better engage and collaborate with patients and the public, ensuring their voices are heard and their experiences shape our research.
  6. Integrating Research into Care: Our ultimate goal is to seamlessly integrate cancer research into the delivery of cancer care. By leveraging high-level genomics expertise and molecular tumour boards, we can revolutionise the way cancer is understood and treated.

None of this progress would be possible without the generous cooperative funding that we receive. We're grateful for the support from UCD, St Vincent’s University Hospital, the Mater Misericordiae University Hospital, and the Health Research Board (Grant reference CTIC-2021-003).

Together, we're on a mission to transform cancer research and improve the lives of patients. Join us on this incredible journey toward a future where cancer is better understood, better treated, and ultimately defeated.

Publication Spotlight

Graphic with text next to a megaphone. The text says
Read more about new treatments for cancer-related menopause, lymphoma translational research, and the interim results of the NATALEE trial.
Three overlapping journal covers overlaid with the text 'january publication update'
Read more about social inclusion in cancer, attempts to address treatment resistance in melanoma, and results of a new treatment for cervical cancer.
(opens in a new window)
The logo for the journal, with a red circular stamp and black text Cancer Treatment and Pregnancy
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

Publication List

Our 2024 list of publications include articles produced by our cluster's researchers as well as publications arising from the hard work of our trial units at St Vincent's University Hospital and The Mater Misericordiae University Hospital.

  • Slamon, D. J., Diéras, V., Rugo, H. S., Harbeck, N., Im, S. A., Gelmon, K. A., ... & Finn, R. S. (2024). Overall survival with palbociclib plus letrozole in advanced breast cancer. Journal of Clinical Oncology, 42(9), 994.
  • Keating, M., Ferrada, P., O'Halloran, P. J., Perry, W., Potter, S., Reddy, S. S., ... & Reynolds, I. S. (2024). Tips for early career academic surgeons. The American Journal of Surgery.
  • Connor, K., Conroy, E., White, K., Shiels, L. P., Keek, S., Ibrahim, A., ... & Byrne, A. T. (2024). A clinically relevant computed tomography (CT) radiomics strategy for intracranial rodent brain tumour monitoring. Scientific Reports, 14(1), 2720.
  • Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Symeonides, S., Hajek, J., ... & Powles, T. (2024). Patient-reported outcomes in KEYNOTE-564: adjuvant pembrolizumab versus placebo for renal cell carcinoma. The Oncologist, 29(2), 142-150.
  • Kenny, C., Regan, J., Balding, L., Higgins, S., O'Leary, N., Kelleher, F., ... & Walsh, D. (2024). Oxaliplatin-related dysphagia: Mixed-methods study. BMJ Supportive & Palliative Care.
  • AlSendi M, Flynn C, Khan M, Selvadurai P, Crown J, McDermott R..... Higgins M, (2024). Pilot study of the implementation of G8 screening tool, Cognitive screening assessment and Chemotherapy Toxicity assessment in older adults with cancer in a Tertiary University Hospital in Ireland.. Irish journal of medical science, 193 (1), pp. 45-50
  • Mamounas, E. P., Bandos, H., Rastogi, P., Zhang, Y., Treuner, K., Lucas, P. C., ... & Wolmark, N. (2024). Breast cancer index and prediction of extended aromatase inhibitor therapy benefit in hormone receptor-positive breast cancer from the NRG Oncology/NSABP B-42 trial. Clinical Cancer Research, OF1-OF8.
  • Macleod, H., Weiss, L., Kelliher, S., Kevane, B., Ní Áinle, F., & Maguire, P. B. (2024). The effect of UVA light/8-methoxypsoralen exposure used in Extracorporeal Photopheresis treatment on platelets and extracellular vesicles. Plos one, 19(2), e0293687.
  • McSorley, L. M., Tharmabala, M., Al Rahbi, F., Keane, F., Evoy, D., Geraghty, J. G., ... & Walshe, J. M. (2024). Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland. Current Oncology, 31(3), 1302-1310.
  • Donohoe, F., O’Meara, Y., Roberts, A., Comerford, L., Valcheva, I., Kearns, U., ... & Brennan, D. J. (2024). Multimodal, Technology-Assisted Intervention for the Management of Menopause after Cancer Improves Cancer-Related Quality of Life—Results from the Menopause after Cancer (Mac) Study. Cancers, 16(6), 1127.
  • Slamon, D., Lipatov, O., Nowecki, Z., McAndrew, N., Kukielka-Budny, B., Stroyakovskiy, D., ... & Hortobagyi, G. (2024). Ribociclib plus Endocrine Therapy in Early Breast Cancer. New England Journal of Medicine, 390(12), 1080-1091.
  • Walsh, M., Jordan, A., Schäfer, L., Joha, J., Heapes, B., Noonan, M., ... & UCD Prostate Patient Advisory Committee. (2024). IMPROVER (Involving Men with Prostate Cancer in Engaged Research): Assessing Patient Experience With Testing, Diagnosis, And Surveillance. Clinical Genitourinary Cancer, 22(3), 102063.
  • Treacy, T., O'Meara, Y., Galligan, M. C., Henry, A. L., Lensen, S. F., Higgins, M. J., ... & Brennan, D. J. (2024). The Sleepio after cancer (SAC) study. Digital cognitive behavioural therapy for insomnia (dCBT-I) in women cancer patients–Trial protocol of a randomised controlled trial. Contemporary Clinical Trials, 136, 107337.
  • Chen, N., McGrath, C. B., Ericsson, C. I., Vaselkiv, J. B., Rencsok, E. M., Stopsack, K. H., ... & Mucci, L. A. (2024). Marital status, living arrangement, and survival among individuals with advanced prostate cancer in the International Registry for Men with Advanced Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention.
  • Carpenter, C., O’Farrell, A., Áinle, F. N., Cheallaigh, C. N., & Kevane, B. (2024). Retrospective cross-sectional analysis of concurrent VTE diagnosis in hospitalised socially excluded individuals in Ireland. BMJ open, 14(1), e073718.
  • Weiss, L., Uhrig, W., Kelliher, S., Szklanna, P. B., Prendiville, T., Comer, S. P., ... & Maguire, P. B. (2024). Proteomic analysis of extracellular vesicle cargoes mirror the cardioprotective effects of rivaroxaban in patients with venous thromboembolism. PROTEOMICS–Clinical Applications, 2300014.
  • Jahangir, C. A., Page, D. B., Broeckx, G., Gonzalez, C. A., Burke, C., Murphy, C., ... & Rahman, A. (2024). Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer. The Journal of Pathology.
  • Mahgoub, T. M., Jordan, E. J., Mahdi, A. F., Oettl, V., Huefner, S., O’Donovan, N., ... & Collins, D. M. (2024). Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells. Cancer Chemotherapy and Pharmacology, 1-11.
  • Kennedy, S., Owens, S., Ivers, L., Hegarty, C., O’Neill, V., Berenguer-Pina, J. J., ... & Walsh, N. (2024). Prognostic Value of BAP1 Protein Expression in Uveal Melanoma. The American Journal of Surgical Pathology, 10-1097.

Our 2023 list of publications include articles produced by our cluster's researchers as well as publications arising from the hard work of our trial units at St Vincent's University Hospital and The Mater Misericordiae University Hospital.

  • Westphalen, C. B., Federer-Gsponer, J., Pauli, C., Karapetyan, A. R., Chalabi, N., Durán-Pacheco, G., ... & Krämer, A. (2023). Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study. ESMO open, 8(6), 102035.
  • Vergote, I., Van Nieuwenhuysen, E., O'Cearbhaill, R. E., Westermann, A., Lorusso, D., Ghamande, S., ... & Monk, B. J. (2023). Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205/GOG-3024/ENGOT-cx8 study. Journal of clinical oncology, 41(36), 5536.
  • Jhaveri, K., O’Shaughnessy, J., Fasching, P. A., Tolaney, S. M., Yardley, D. A., Sharma, V. K., ... & Rugo, H. S. (2023). Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer. Therapeutic Advances in Medical Oncology, 15, 17588359231216095.
  • Dalli, J., Epperlein, J. P., Jindal, A., Potter, S., & Cahill, R. A. (2023). A Case Report Demonstrating Quantitative Indocyanine Green Fluorescence Angiography for Single-Versus Dual-vein Microvascular Anastomosis. Plastic and Reconstructive Surgery–Global Open, (12), e5468.
  • Lynch, E., Duffy, A. G., & Kelly, R. J. (2023). Role of Immunotherapy in Gastroesophageal Cancers—Advances, Challenges and Future Strategies. Cancers, 15(22), 5401.
  • Kim, H. R., Awad, M. M., Navarro, A., Gottfried, M., Peters, S., Csőszi, T., ... & Rudin, C. M. (2023). Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small Cell Lung Cancer. JTO Clinical and Research Reports, 4(11), 100572.
  • Ronan, K., Jordan, E., Leonard, C., & McDermott, R. (2023). Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data. Irish Journal of Medical Science (1971-), 1-7.
  • Duffy, M. J., & Crown, J. (2023). Circulating tumor DNA (ctDNA): can it be used as a pan-cancer early detection test?. Critical Reviews in Clinical Laboratory Sciences, 1-13.
  • McMahon, M. E., O'Brien, L., Heary, T., Potter, S., & O'Sullivan, B. (2023). Management of the intraoperative loss of microsurgical needles: A literature review and clinical survey. The Surgeon. 
  • Murtagh, G., Januzzi, J. L., Scherrer‐Crosbie, M., Neilan, T. G., Dent, S., Ho, J. E., ... & Akhter, N. (2023). Circulating Cardiovascular Biomarkers in Cancer Therapeutics‐Related Cardiotoxicity: Review of Critical Challenges, Solutions, and Future Directions. Journal of the American Heart Association, 12(21), e029574.
  • Cosgrove, N., Eustace, A. J., O’Donovan, P., Madden, S. F., Moran, B., Crown, J., ... & Furney, S. J. (2023). Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer. NPJ Breast Cancer, 9(1), 72.
  • Kummar, S., Shen, L., Hong, D. S., McDermott, R., Keedy, V. L., Casanova, M., ... & Tan, D. S. (2023). Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. Cancer, 129(23), 3772-3782.
  • O’Reilly, M., & Higgins, M. (2023). Evolving role of liquid biopsies in management of breast cancer. Hospital Professional News. https://hospitalprofessionalnews.ie/2023/02/14/evolving-role-of-liquid-biopsies-in-management-of-breast-cancer/
  • Reynolds, J. V., Preston, S. R., O'Neill, B., Lowery, M. A., Baeksgaard, L., Crosby, T., ... & O'Sullivan, J. (2023). Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. The Lancet Gastroenterology & Hepatology.
  • O’Reilly, E., Khalifa, K., Cosgrave, J., Azam, H., Prencipe, M., Simpson, J. C., ... & Perry, A. S. (2023). Cannabidiol Inhibits the Proliferation and Invasiveness of Prostate Cancer Cells. Journal of Natural Products.
  • Fong, C. H., Meti, N., Kruser, T., Weiss, J., Liu, Z. A., Takami, H., ... & Shultz, D. B. (2023). Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: an international survey of clinical practice. Journal of Thoracic Disease, 15(8), 4367.
  • Lynch, E., Duffy, A. G., & Kelly, R. J. (2023). Brave new world-new and emerging treatments for gastric cancer. Chinese Clinical Oncology, cco-23.
  • Kieran, R., Mitchell, T., Fazari, A. A., Chinoy, A., Moloney, C., & McCaffrey, J. (2023). DPD deficiency in an Irish oncology centre: Prevalence and clinical implications. Journal of Oncology Pharmacy Practice, 10781552231192107.
  • Thagaard, J., Broeckx, G., Page, D. B., Jahangir, C. A., Verbandt, S., Kos, Z., ... & Salgado, R. (2023). Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the international immuno-oncology biomarker working group. The Journal of Pathology.
  • Page, D. B., Broeckx, G., Jahangir, C. A., Verbandt, S., Gupta, R. R., Thagaard, J., ... & Bouchmaa, N. (2023). Spatial analyses of immune cell infiltration in cancer: current methods and future directions. A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. The Journal of Pathology.
  • Beauchamp, K., Moran, B., O’Brien, T., Brennan, D., Crown, J., Sheahan, K., & Cotter, M. B. (2023). Carcinoma of unknown primary (CUP): an update for histopathologists. Cancer and Metastasis Reviews, 1-12.
  • Azam, H., Maher, S., Clarke, S., Gallagher, W. M., & Prencipe, M. (2023). SRF inhibitors reduce prostate cancer cell proliferation through cell cycle arrest in an isogenic model of castrate-resistant prostate cancer. Cell Cycle, 1-18.
  • Donnelly, M., Ryan, O. K., Ryan, É. J., Creavin, B., O’Reilly, M., McDermott, R., ... & Winter, D. C. (2023). Total neoadjuvant therapy versus standard neoadjuvant treatment strategies for the management of locally advanced rectal cancer: network meta-analysis of randomized clinical trials. British Journal of Surgery, znad177.
  • Carolan, D., Milling, R., Quinlan, C., Carr, S., Kinsella, A., McDermott, B. R., ... & Potter, S. (2023). Are Plastic Surgery Trainees Accurate Assessors of Their Own Microsurgical Skill?. JPRAS open.
    Flynn, C. R., Kumar, A. P., O'Shea, D., & Higgins, M. J. (2023). Alpelisib-induced thyroiditis in a patient with metastatic breast cancer: Is routine monitoring of thyroid function required?. Current Problems in Cancer: Case Reports, 9, 100219.
  • Silva, R., Glennon, K., Metoudi, M., Moran, B., Salta, S., Slattery, K., ... & Brennan, D. J. (2023). Unveiling the epigenomic mechanisms of acquired platinum‐resistance in high‐grade serous ovarian cancer. International Journal of Cancer, 153(1), 120-132.
  • Tang, M., Crown, J., & Duffy, M. J. (2023). Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells. Investigational New Drugs, 1-10.
  • Slamon, D. J., Fasching, P. A., Hurvitz, S., Chia, S., Crown, J., Martín, M., ... & Hortobagyi, G. N. (2023). Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib+ endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer. Therapeutic Advances in Medical Oncology, 15, 17588359231178125.
  • Myers, C., Bennett, K., Kelly, C., Walshe, J., O’Sullivan, N., Quinn, M., ... & Cahir, C. (2023). Impact of COVID-19 on health care and quality of life in women with breast cancer. JNCI Cancer Spectrum, 7(3), pkad033.
  • Mamounas, E. P., Bandos, H., Rastogi, P., Lembersky, B. C., Jeong, J. H., Geyer Jr, C. E., ... & Wolmark, N. (2023). Ten-year Update: NRG Oncology/NSABP B-42 Randomized Trial: Extended Letrozole Therapy in Early-stage Breast Cancer. JNCI: Journal of the National Cancer Institute, djad078.
  • Antonarakis, E. S., Park, S. H., Goh, J. C., Shin, S. J., Lee, J. L., Mehra, N., McDermott, R., Sala-Gonzalez, N., Fong, P. C., Greil, R., Retz, M., Sade, J. P., Yanez, P., Huang, Y. H., Begbie, S. D., Gafanov, R. A., De Santis, M., Rosenbaum, E., Kolinsky, M. P., Rey, F., … Yu, E. Y. (2023). Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2300233. Advance online publication. https://doi.org/10.1200/JCO.23.00233
  • Partridge, A. H., Niman, S. M., Ruggeri, M., Peccatori, F. A., Azim Jr, H. A., Colleoni, M., ... & Pagani, O. (2023). Interrupting endocrine therapy to attempt pregnancy after breast cancer. New England Journal of Medicine, 388(18), 1645-1656.
  • Abida, W., Campbell, D., Patnaik, A., Bryce, A. H., Shapiro, J., Bambury, R. M., ... & Chowdhury, S. (2023). Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. European Urology.
  • Sheill, G., Brady, L., Hayes, B., Baird, A. M., Guinan, E., Vishwakarma, R., ... & Finn, S. (2023). ExPeCT: a randomised trial examining the impact of exercise on quality of life in men with metastatic prostate cancer. Supportive Care in Cancer, 31(5), 292.
  • Early Breast Cancer Trialists’ Collaborative Group. (2023). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. The Lancet, 401(10384), 1277-1292.
  • Denkert, C., Lambertini, C., Fasching, P. A., Pogue-Geile, K. L., Mano, M. S., Untch, M., ... & Basik, M. (2023). Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer. Clinical Cancer Research, 29(8), 1569-1581.
  • Harvey, H., Carroll, H., Murphy, V., Ballot, J., O'Grady, M., O'Hare, D., ... & O'Reilly, S. (2023). The Impact of a National Cyberattack Affecting Clinical Trials: The Cancer Trials Ireland Experience. JCO Clinical Cancer Informatics, 7, e2200149.
  • Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., ... & Usmani, S. Z. (2019). Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. New England Journal of Medicine, 380(22), 2104-2115.
  • Roche, S., Gaule, P., Winrow, D., Mukherjee, N., O’Neill, F., Conlon, N. T., ... & Eustace, A. J. (2023). Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer. Plos one, 18(3), e0282512.
  • Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., ... & Bryce, A. H. (2023). Rucaparib or physician’s choice in metastatic prostate cancer. New England Journal of Medicine, 388(8), 719-732.
  • de Azambuja, E., Agostinetto, E., Procter, M., Eiger, D., Pondé, N., Guillaume, S., ... & Committee, A. S. (2023). Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positivebreast cancer in the APHINITY trial. ESMO Open, 8(1), 100772.
  • Monge, C., Xie, C., Myojin, Y., Coffman, K., Hrones, D. M., Wang, S., ... & Greten, T. F. (2023). Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. Journal for Immunotherapy of Cancer, 11(2).
  • O’Neill, F., Allen-Coyle, T. J., Roche, S., Meiller, J., Conlon, N. T., Swan, N., ... & Clynes, M. (2023). Alteration in Levels of Specific miRNAs and Their Potential Protein Targets between Human Pancreatic Cancer Samples, Adjacent Normal Tissue, and Xenografts Derived from These Tumors. Life, 13(3), 608.
  • O’Reilly, M., Linehan, A., Krstic, A., Kolch, W., Sheahan, K., Winter, D. C., & Mc Dermott, R. (2023). Oncotherapeutic Strategies in Early Onset Colorectal Cancer. Cancers, 15(2), 552.
  • Lynch, E., Duffy, A. G., & Kelly, R. J. (2023). Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma. Pharmaceuticals, 16(1), 102. 

Our 2022 list of publications include articles produced by our cluster's researchers as well as publications arising from the hard work of our trial units at St Vincent's University Hospital and The Mater Misericordiae University Hospital.

  • Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., ... & Mayer, E. L. (2022). Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03). Journal of Clinical Oncology, 40(3), 282.
  • Kelliher, S., Ní Áinle, F., Weiss, L., Gamba, S., Fouhy, E., Marchetti, M., ... & Kevane, B. (2022). Analysis of the Platelet Proteome Reveals Insights into the Pro-Inflammatory and Pro-Thrombotic State Associated with the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Blood, 140(Supplement 1), 2654-2655.
  • Cowzer, D., Zameer, M., Conroy, M., Kolch, W., & Duffy, A. G. (2022). Targeting KRAS in Pancreatic Cancer. Journal of Personalized Medicine, 12(11), 1870.
  • Mucci, L. A., Vinson, J., Gold, T., Gerke, T., Filipenko, J., Green, R. M., ... & IRONMAN Global Team. (2022). IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer. JCO Global Oncology, 8, e2200154.
  • Duffy, M. J., Mullooly, M., Bennett, K., & Crown, J. (2022). Vitamin D Supplementation: Does It Have a Preventative or Therapeutic Role in Cancer?. Nutrition and Cancer, 1-11.
  • McNevin, C. S., Cadoo, K., Baird, A. M., Finn, S. P., & McDermott, R. (2022). PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures. Cancers, 14(19), 4751.
  • Carroll, H. K., Higgins, M. J., & O'Reilly, S. (2022). Trastuzumab Deruxtecan in HER2-Low Breast Cancer. The New England journal of medicine, 387(12), 1144.
  • Duffy, M. J., Tang, M., Rajaram, S., O’Grady, S., & Crown, J. (2022). Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?. Cancers, 14(18), 4499.
  • Powles, T., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., … KEYNOTE-564 Investigators (2022). Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 23(9), 1133–1144. https://doi.org/10.1016/S1470-2045(22)00487-9
  • Duffy, M. J., & Crown, J. (2022). Circulating Tumor DNA as a Biomarker for Monitoring Patients with Solid Cancers: Comparison with Standard Protein Biomarkers. Clinical Chemistry, 68(11), 1381-1390.
  • Ding, X., Sharko, A. C., McDermott, M. S., Schools, G. P., Chumanevich, A., Ji, H., ... & Broude, E. V. (2022). Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo. Proceedings of the National Academy of Sciences, 119(32), e2201073119.
  • Mukherjee, N., Browne, A., Ivers, L., Santra, T., Cremona, M., Hennessy, B. T., ... & Eustace, A. J. (2022). A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin. Journal of Personalized Medicine, 12(8), 1277.
  • Tang, M., O’Grady, S., Crown, J., & Duffy, M. J. (2022). MYC as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigations with the novel MYC inhibitor, MYCi975. Breast Cancer Research and Treatment, 195(2), 105-115.
  • Aladaileh, M., Moran, T., Duffy, A., Redmond, K., & O'Briain, D. (2022). Multispecialty surgical management of large clavicular tumor: A case report. International Journal of Surgery Case Reports, 97, 107375.
  • Antoranz, A., Van Herck, Y., Bolognesi, M. M., Lynch, S. M., Rahman, A., Gallagher, W. M., ... & Bosisio, F. M. (2022). Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cell–Cell Interactions That Predict Immunotherapy Response. Cancer Research, 82(18), 3275-3290.
  • Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., ... & Cameron, D. A. (2022). Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. New England Journal of Medicine, 387(1), 9-20.
  • Andrieu, C., McNamee, N., Larkin, A. M., Maguire, A., Menon, R., Mueller-Eisert, J., ... & Walsh, N. (2022). Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes. Medical Sciences, 10(2), 26.
  • André, T., Lonardi, S., Wong, K. Y. M., Lenz, H. J., Gelsomino, F., Aglietta, M., ... & Overman, M. J. (2022). Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Annals of Oncology, 33(10), 1052-1060.
  • Gallagher, A., Murphy, M., McDermott, R., Alexander, M., & O'Dowd, S. (2022). Pembrolizumab‐Induced Steroid‐Responsive Myoclonus. Movement Disorders Clinical Practice, 9(4), 546.
  • O’Reilly, S., Murphy, V., Mulroe, E., Tucker, L., Carragher, F., Marron, J., ... & McDermott, R. S. (2022). The SARS-CoV-2 pandemic and cancer trials Ireland: impact, resolution and legacy. Cancers, 14(9), 2247.
  • Le, X., Baik, C., Bauman, J., Gilbert, J., Brose, M. S., Grilley-Olson, J. E., ... & Hong, D. S. (2022). Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers. The Oncologist.
  • Miller, I. S., Khan, S., Shiels, L. P., Das, S., O'Farrell, A. C., Connor, K., ... & Byrne, A. T. (2022). Implementing subtype‐specific pre‐clinical models of breast cancer to study pre‐treatment aspirin effects. Cancer Medicine, 11(20), 3820-3836.
  • Fizazi, K., Foulon, S., Carles, J., Roubaud, G., McDermott, R., Fléchon, A., ... & Bossi, A. (2022). Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2× 2 factorial design. The Lancet, 399(10336), 1695-1707.
  • Belltall, A., Zúñiga-Trejos, S., Garrido-Cano, I., Eroles, P., Argente-Navarro, M. P., Buggy, D. J., ... & Mazzinari, G. (2022). Solid Tumor Opioid Receptor Expression and Oncologic Outcomes: Analysis of the Cancer Genome Atlas and Genotype Tissue Expression Project. Frontiers in Oncology, 12.
  • Udayakumar, S., Parmar, A., Leighl, N. B., Everest, L., Arciero, V. S., Santos, S. D., ... & Chan, K. K. (2022). Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology, 103660.
  • Waguespack, S. G., Drilon, A., Lin, J. J., Brose, M. S., McDermott, R., Almubarak, M., ... & Cabanillas, M. E. (2022). Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. European journal of endocrinology, 186(6), 631-643.
  • Reynolds, I. S., Cromwell, P. M., Walshe, J. M., Crown, J., Maguire, D., Geoghegan, J., ... & Hoti, E. (2022). Hepatic resection for breast cancer related liver metastases: A single institution experience. Scandinavian Journal of Surgery, 111(1), 14574969221088685.
  • Loughman, T., Barron, S., Wang, C. J. A., Dynoodt, P., Fender, B., Lopez-Ruiz, C., ... & Gallagher, W. M. (2022). Analytical validation of a novel 6-gene signature for prediction of distant recurrence in estrogen receptor-positive, HER2-negative, early-stage breast cancer. Clinical Chemistry, 68(6), 837-847.
  • Carroll, H. K., Duffy, A. G., & O'Farrelly, C. (2022, March). Liver Immunology, Immunotherapy, and Liver Cancers: Time for a Rethink?. In Seminars in Liver Disease. Thieme Medical Publishers, Inc..
  • Shrestha, A., Cullinane, C., Evoy, D., Geraghty, J., Rothwell, J., Walshe, J., ... & Prichard, R. (2022). Clinical Treatment Score post-5 years as a predictor of late distant recurrence in hormone receptor-positive breast cancer: Systematic review and meta-analysis. British Journal of Surgery, 109(5), 411-417.
  • Donohoe, F., O’Meara, Y., Roberts, A., Comerford, L., Kelly, C. M., Walshe, J. M., ... & Brennan, D. J. (2023). Using menopausal hormone therapy after a cancer diagnosis in Ireland. Irish Journal of Medical Science (1971-), 192(1), 45-55.
  • Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., ... & O’shaughnessy, J. (2022). Event-free survival with pembrolizumab in early triple-negative breast cancer. New England Journal of Medicine, 386(6), 556-567.
  • Kenny, C., Regan, J., Balding, L., Higgins, S., O'Leary, N., Kelleher, F., ... & Walsh, D. (2022). Dysphagia in Solid Tumors Outside the Head, Neck or Upper GI Tract: Clinical Characteristics. Journal of Pain and Symptom Management, 64(6), 546-554.
  • Peddi, P. F., Fasching, P. A., Liu, D., Quinaux, E., Robert, N. J., Valero, V., ... & Hurvitz, S. A. (2022). Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. Clinical Cancer Research, 28(9), 1854-1862.
  • Wahlin, S., Boman, K., Moran, B., Nodin, B., Gallagher, W. M., Karnevi, E., & Jirström, K. (2022). Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity. BMC cancer, 22(1), 131.
  • Duffy, M. J., & Crown, J. (2022). Use of circulating tumour DNA (ctDNA) for measurement of therapy predictive biomarkers in patients with cancer. Journal of Personalized Medicine, 12(1), 99.
  • Howard, J., Goh, C. Y., Gorzel, K. W., Higgins, M., & McCann, A. (2022). The potential role of cofilin-1 in promoting triple negative breast cancer (TNBC) metastasis via the extracellular vesicles (EVs). Translational oncology, 15(1), 101247.

Our funders and partners

On this page

Contact the UCD Cancer Trials Cluster

UCD Clinical Research Centre, St Vincent's University Hospital, Elm Park, Dublin 4
E: cancertrials@ucd.ie